Dr Reddy's Laboratories was down 1.91% to Rs 2,512.85 at 13:41 IST on BSE after consolidated net profit fell 39.13% to Rs 294.20 crore on 2.97% growth in total revenue from operations to Rs 3834.10 crore in Q3 December 2017 over Q3 December 2016.
The result was announced during market hours today, 25 January 2018.Meanwhile, the S&P BSE Sensex was down 231.97 points or 0.64% at 35,929.67.
On the BSE, 1.21 lakh shares were traded on the counter so far as against average daily volumes of 53,010 shares in the past one quarter. The stock had hit a high of Rs 2,594.95 and a low of Rs 2,458.95 so far during the day. The stock had hit a 52-week high of Rs 3,175 on 6 February 2017 and a 52-week low of Rs 1,901.65 on 11 August 2017.
The large-cap company has equity capital of Rs 82.95 crore. Face value per share is Rs 5.
Dr Reddy's Laboratories is an integrated global pharmaceutical company.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app